Cargando…

Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

Up to 25% of patients with profound neutropenia lasting for >10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority of cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Maschmeyer, G., Carratalà, J., Buchheidt, D., Hamprecht, A., Heussel, C.P., Kahl, C., Lorenz, J., Neumann, S., Rieger, C., Ruhnke, M., Salwender, H., Schmidt-Hieber, M., Azoulay, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: THE AUTHORS. Published by Elsevier Ltd. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269340/
https://www.ncbi.nlm.nih.gov/pubmed/24833776
http://dx.doi.org/10.1093/annonc/mdu192
_version_ 1782349346776285184
author Maschmeyer, G.
Carratalà, J.
Buchheidt, D.
Hamprecht, A.
Heussel, C.P.
Kahl, C.
Lorenz, J.
Neumann, S.
Rieger, C.
Ruhnke, M.
Salwender, H.
Schmidt-Hieber, M.
Azoulay, E.
author_facet Maschmeyer, G.
Carratalà, J.
Buchheidt, D.
Hamprecht, A.
Heussel, C.P.
Kahl, C.
Lorenz, J.
Neumann, S.
Rieger, C.
Ruhnke, M.
Salwender, H.
Schmidt-Hieber, M.
Azoulay, E.
author_sort Maschmeyer, G.
collection PubMed
description Up to 25% of patients with profound neutropenia lasting for >10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority of cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk patients who have received trimethoprim–sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear to be predominant, yet commonly not proven at the time of treatment initiation. Pathogens isolated from blood cultures, bronchoalveolar lavage (BAL) or respiratory secretions are not always relevant for the etiology of pulmonary infiltrates and should therefore be interpreted critically. Laboratory tests for detecting Aspergillus galactomannan, β-d-glucan or DNA from blood, BAL or tissue samples may facilitate the diagnosis; however, most polymerase chain reaction assays are not yet standardized and validated. Apart from infectious agents, pulmonary side-effects from cytotoxic drugs, radiotherapy or pulmonary involvement by the underlying malignancy should be included into differential diagnosis and eventually be clarified by invasive diagnostic procedures. Pre-emptive treatment with mold-active systemic antifungal agents improves clinical outcome, while other microorganisms are preferably treated only when microbiologically documented. High-dose TMP/SMX is first choice for treatment of Pneumocystis pneumonia, while cytomegalovirus pneumonia is treated primarily with ganciclovir or foscarnet in most patients. In a considerable number of patients, clinical outcome may be favorable despite respiratory failure, so that intensive care should be unrestrictedly provided in patients whose prognosis is not desperate due to other reasons.
format Online
Article
Text
id pubmed-4269340
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher THE AUTHORS. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-42693402015-03-24 Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) Maschmeyer, G. Carratalà, J. Buchheidt, D. Hamprecht, A. Heussel, C.P. Kahl, C. Lorenz, J. Neumann, S. Rieger, C. Ruhnke, M. Salwender, H. Schmidt-Hieber, M. Azoulay, E. Ann Oncol Article Up to 25% of patients with profound neutropenia lasting for >10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority of cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk patients who have received trimethoprim–sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear to be predominant, yet commonly not proven at the time of treatment initiation. Pathogens isolated from blood cultures, bronchoalveolar lavage (BAL) or respiratory secretions are not always relevant for the etiology of pulmonary infiltrates and should therefore be interpreted critically. Laboratory tests for detecting Aspergillus galactomannan, β-d-glucan or DNA from blood, BAL or tissue samples may facilitate the diagnosis; however, most polymerase chain reaction assays are not yet standardized and validated. Apart from infectious agents, pulmonary side-effects from cytotoxic drugs, radiotherapy or pulmonary involvement by the underlying malignancy should be included into differential diagnosis and eventually be clarified by invasive diagnostic procedures. Pre-emptive treatment with mold-active systemic antifungal agents improves clinical outcome, while other microorganisms are preferably treated only when microbiologically documented. High-dose TMP/SMX is first choice for treatment of Pneumocystis pneumonia, while cytomegalovirus pneumonia is treated primarily with ganciclovir or foscarnet in most patients. In a considerable number of patients, clinical outcome may be favorable despite respiratory failure, so that intensive care should be unrestrictedly provided in patients whose prognosis is not desperate due to other reasons. THE AUTHORS. Published by Elsevier Ltd. 2015-01 2020-01-06 /pmc/articles/PMC4269340/ /pubmed/24833776 http://dx.doi.org/10.1093/annonc/mdu192 Text en © 2015 THE AUTHORS Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Maschmeyer, G.
Carratalà, J.
Buchheidt, D.
Hamprecht, A.
Heussel, C.P.
Kahl, C.
Lorenz, J.
Neumann, S.
Rieger, C.
Ruhnke, M.
Salwender, H.
Schmidt-Hieber, M.
Azoulay, E.
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
title Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
title_full Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
title_fullStr Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
title_full_unstemmed Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
title_short Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
title_sort diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic sct excluded): updated guidelines of the infectious diseases working party (agiho) of the german society of hematology and medical oncology (dgho)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269340/
https://www.ncbi.nlm.nih.gov/pubmed/24833776
http://dx.doi.org/10.1093/annonc/mdu192
work_keys_str_mv AT maschmeyerg diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT carratalaj diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT buchheidtd diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT hamprechta diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT heusselcp diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT kahlc diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT lorenzj diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT neumanns diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT riegerc diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT ruhnkem diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT salwenderh diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT schmidthieberm diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho
AT azoulaye diagnosisandantimicrobialtherapyoflunginfiltratesinfebrileneutropenicpatientsallogeneicsctexcludedupdatedguidelinesoftheinfectiousdiseasesworkingpartyagihoofthegermansocietyofhematologyandmedicaloncologydgho